Business Context and Reporting Period
Company: IRIDEX Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 30, 2006
Business Overview: IRIDEX is a worldwide provider of therapeutic laser systems for ophthalmology (eye diseases) and dermatology (skin conditions). The company sells primarily through a direct U.S. sales force and 77 international distributors. In January 2007, the company acquired the aesthetics business of Laserscope to expand its dermatology portfolio.
Key Financial Metrics
| Metric | 2006 | 2005 | 2004 |
|---|---|---|---|
| Total Revenue | $35.9 million | $37.0 million | $32.8 million |
| Gross Profit | $18.8 million | $18.2 million | $14.9 million |
| Gross Margin | 52.4% | 49.1% | 45.4% |
| Net Income (Loss) | ($5.8) million | $1.7 million | ($0.4) million |
| EPS (Basic) | ($0.75) | $0.23 | ($0.06) |
| Cash & Equivalents (Year End) | $21.1 million | $12.7 million | $10.4 million |
| Working Capital | $29.8 million | $32.3 million | $25.3 million |
| Debt Outstanding (Year End) | $0 | $0 | $0 |
Note: Debt of $12 million was incurred in January 2007 to finance the Laserscope acquisition, subsequent to the reporting period.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 3.0% to $35.9 million. This was driven by a 26.5% drop in domestic dermatology sales, partially offset by a 2.4% increase in domestic ophthalmology sales.
- Operating Loss: The company reported a net loss of $5.8 million in 2006 compared to a net income of $1.7 million in 2005. This reversal was primarily due to a 48.4% increase in Selling, General, and Administrative (SG&A) expenses.
- Expense Surge: SG&A expenses rose to $18.1 million from $12.2 million. Key drivers included $2.4 million in increased legal spending (litigation), $1.0 million in stock compensation expense, and $0.5 million in fees related to an internal investigation of revenue recognition policies.
- Recurring Revenue Growth: Recurring revenue (disposables and service) increased to 43% of total business in 2006, up from 36% in 2005.
- Stock-Based Compensation: The company adopted SFAS 123(R) in 2006, recognizing $1.8 million in stock-based compensation expense, which was not recorded in prior periods under the previous accounting method.
Guidance, Outlook, Risks, and Contingencies
Liquidity and Going Concern
The auditors (PricewaterhouseCoopers LLP) issued a "going concern" opinion, stating there is substantial doubt about the company's ability to continue operations for the next 12 months. The company expects to be unable to satisfy restrictive covenants in its credit facilities (Mid-Peninsula Bank and Export-Import Bank) as of March 31, 2007. These facilities, totaling $12 million, were drawn down in January 2007 to fund the Laserscope acquisition.
Outlook and Strategy
Management plans to address liquidity by integrating the Laserscope business, modifying operations to increase cash flow, restructuring credit facilities, and raising additional capital. Future growth is expected to rely on the Laserscope acquisition, new product introductions (e.g., yellow 577nm laser), and increasing recurring revenue from disposable probes.
Risks and Contingencies
- Legal Proceedings: The company is engaged in patent litigation with Synergetics, Inc. regarding laser probe technology. Trial is scheduled for April 2007. Management believes liabilities will not be material, but legal costs are significant.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding period-end review procedures and revenue recognition. Remediation plans are underway.
- Debt Covenants: Failure to meet profitability and tangible net worth covenants could result in the acceleration of debt repayment, potentially forcing the company to cease operations.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the status of discussions with lenders (Mid-Peninsula Bank/Exim Bank) regarding the restructuring of credit facilities and the likelihood of avoiding default.
- Capital Raising: Monitor announcements regarding equity or debt financing efforts to address the liquidity shortfall.
- Laserscope Integration: Assess the progress of integrating the Laserscope aesthetics business and whether it is generating the anticipated revenue to offset increased debt service.
- Legal Costs: Track ongoing legal expenses related to the Synergetics litigation and the internal revenue recognition investigation.
- Internal Controls: Review future filings (10-Q) for updates on the remediation of material weaknesses in financial reporting controls.